EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Paraoxonase 1 Suppresses Hepatocellular Carcinoma Progression by Modulating the NOD-like Receptor Signaling Pathway

Hao-Lin Wei, Zhi-Ce Tan, Chu-Heng Gou iD, Ling Wang, Ze-Kun Liu iD, Hui-Jie Bian iD

Biomolecules · 25.05.2026 · 16 (6) · 774

DOI: 10.3390/biom16060774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 25.05.2026. Verfasst von Hao-Lin Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an 710032, China. Hauptthemen laut MEDLINE: Aryldialkylphosphatase, Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, the State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) represents one of the most lethal malignancies worldwide and is characterized by profound metabolic reprogramming during its development. Paraoxonase 1 (PON1), a liver-synthesized secretory protein involved in lipid metabolism, has an incompletely defined role in cancer biology. This study aimed to systematically investigate the expression pattern, clinical features, and biological function of PON1 in HCC through an integrated approach combining data mining, RNA-seq and experimental verification. Our results demonstrated that PON1 expression is significantly downregulated in HCC tissues compared with adjacent tissues. Clinically, significant disparities were observed in gender (χ2 = 19.305, p < 0.0001), tumor stage (χ2 = 18.030, p = 0.0004), and tumor grade (χ2 = 13.391, p = 0.0039) between patients with high and low PON1 expression in HCC. Low PON1 expression was associated with poor prognosis (TCGA_LIHC, log-rank: χ2 = 9.290, p = 0.0023; ICGC_LIRI, log-rank: χ2 = 8.469, p = 0.0036; GSE14520, log-rank: χ2 = 9.746, p = 0.0018). Univariate and multivariate Cox regression analyses revealed PON1 as an independent prognostic biomarker. Pathway analysis showed that PON1-positively correlated genes enriched in pathways such as peroxisome and fatty acid degradation, whereas PON1-negatively correlated genes mainly in the cell cycle pathway. Functional experiments confirmed that knockdown of PON1 promoted HCC cell proliferation, migration, invasion and inhibited apoptosis, whereas overexpression of PON1 reversed these malignant phenotypes. Mechanistically, we uncovered that PON1 exerts its tumor-suppressive effects by negatively regulating TANK and CXCL3, key molecules of the NOD-like receptor signaling pathway. In summary, our findings identify PON1 as an independent prognostic biomarker in HCC and demonstrate the tumor-suppressive role of PON1, indicating its potential as a therapeutic target for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AryldialkylphosphataseLiver NeoplasmsCarcinoma, HepatocellularHumansSignal TransductionGene Expression Regulation, NeoplasticPrognosisMaleFemaleCell ProliferationDisease ProgressionCell MovementCell Line, TumorMiddle Aged

Stichwörter der Autor:innen

hepatocellular carcinomaparaoxonase 1prognostic biomarkertumor suppressor factor

Substanzen

AryldialkylphosphatasePON1 protein, human

Autor:innen und Institutionen

  • Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an 710032, China.
  • State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an 710032, China.
  • Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
  • Department of Health Statistics, School of Preventive Medicine, Fourth Military Medical University, Xi'an 710032, China.

ORCID-Profile: Chu-Heng Gou, Ze-Kun Liu, Hui-Jie Bian

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • the State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers
  • Project Program of the State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers

Zitieren

APA

Wei, H. L., Tan, Z. C., Gou, C. H., Wang, L., Liu, Z. K., & Bian, H. J. (2026). Paraoxonase 1 Suppresses Hepatocellular Carcinoma Progression by Modulating the NOD-like Receptor Signaling Pathway. Biomolecules, 16(6), 774. https://doi.org/10.3390/biom16060774

Vancouver

Wei HL, Tan ZC, Gou CH, Wang L, Liu ZK, Bian HJ. Paraoxonase 1 Suppresses Hepatocellular Carcinoma Progression by Modulating the NOD-like Receptor Signaling Pathway. Biomolecules. 2026;16(6):774. doi:10.3390/biom16060774

BibTeX
@article{Wei2026,
  author = {Wei, Hao-Lin and Tan, Zhi-Ce and Gou, Chu-Heng and Wang, Ling and Liu, Ze-Kun and Bian, Hui-Jie},
  title = {Paraoxonase 1 Suppresses Hepatocellular Carcinoma Progression by Modulating the NOD-like Receptor Signaling Pathway},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {774},
  doi = {10.3390/biom16060774}
}
Kostenlos starten →